Table 2.
Biologics in phase II/III trials
| Generic Name | Target | Trial Indications |
|---|---|---|
| Gevokizumab | IL-1β | Diabetes, type II |
| Sifalimumab | IFN-α | Systemic lupus erythematosus |
| Rontalizumab | IFN-α | Systemic lupus erythematosus |
| Clazakizumab | IL-6 | Rheumatoid arthritis |
| Sirutumab | IL-6 | Rheumatoid arthritis Depression |
| Mavrilimumab | GM-CSFRα | Rheumatoid arthritis |
| Ixekizumab | IL-17 | Plaque psoriasis |
| Brodalumab | IL-17R | Plaque psoriasis |
| Tildrakizumab | IL-23 | Plaque psoriasis |
| Guselkumab | IL-23 p19 | Plaque psoriasis |
| Oteliximab | CD3ε | Diabetes, type I |
| Teplizumab | CD3 | Diabetes, type I |
| Visilizumab | CD3 | Inflammatory bowel disease |
| Blisibimod | BAFF | Systemic lupus erythematosus |
| Tabalumab | BAFF | Systemic lupus erythematosus |